Nanodevices have emerged as transformative tools in the field of pharmaceuticals, offering unprecedented opportunities for precision medicine and targeted drug delivery. These miniature devices, typically on the nanometer scale, enable the manipulation and control of biological processes at the molecular level. In the pharmaceutical realm, nanodevices play a pivotal role in enhancing drug efficacy while minimizing side effects. By exploiting their unique properties, such as high surface area and reactivity, nanodevices can be designed to encapsulate, transport, and release therapeutic agents with remarkable precision.
This level of control is particularly crucial in addressing challenges like drug solubility and bioavailability. Furthermore, nanodevices offer the potential for real-time monitoring and diagnostics, facilitating a more personalized approach to patient care. The development of nanodevices in pharmaceuticals represents a promising frontier, promising to revolutionize drug delivery systems and significantly improve the therapeutic outcomes for various medical conditions. As research in nanotechnology continues to advance, the integration of nanodevices in the pharmaceutical field holds great promise for the development of innovative and highly effective therapeutic solutions.
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia